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Abstract: Methicillin-resistant Staphylococcus aureus (S. aureus) (MRSA), resistant to all antibiotics including 
Vancomycin, has been reported in Japan, USA, Canada and Brazil. Hence, the main objective of this study 
was to evaluate the possible presence of Vancomycin resistant or intermediate S.aureus in Karachi. A total of 
850 clinical isolates were collected from two civil hospitals in the city between February 2006 and January 
2007.  They were identified using standard bacteriological methods.Sensitivity to recommended antibiotics 
was determined by disc diffusion, agar dilution, and E-test quantitative minimum inhibitory concentration 
(MIC). Susceptibility to natural or semi-natural products was determined by the agar dilution method. Out of 
850 isolates, 250 were MRSA, of which 22% were resistant to 4 ￿g/ml Vancomycin, 24% to 8 ￿g/ml, 15.2% to 
16 ￿g/ml, 10% to 20 ￿g/ml, and 13.2% to 30 ￿g/ml; the remaining 15.6% were sensitive to all used 
concentrations. Although we did not detect any Vancomycin-resistant S. aureus (VRSA), we found that 13% 
of the strains were intermediates (VISA), i.e. resistant to 30 ￿g/ml of Vancomycin. Because of the 
continuously increasing prevalence of VISA, it is imperative to minimize the use of Vancomycin. Indeed, the 
drug should only be prescribed for the treatment of documented, culture-proven infections with MRSA that are 
not susceptible to routine or alternative agents. This should help avoid the consequences of the development 
of Vancomycin resistant S. aureus (VRSA) in our environment. 
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Introduction 
In the 1970s, MRSA resistant to orally 
administered antibiotics and sensitive only to 
Vancomycin was reported [7]. Since the 1970s 
MRSA has become a nosocomial problem in 
hospitals for both children and adults [26]. MRSA 
may be sensitive to some other antibiotics, such 
as Clindamycin, Macrolides, Tetracyclines, 
Trimethoprim-Sulfamethoxazole and Quinolones, 
or it may be resistant to all antibiotics except 
Vancomycin [8]. Vancomycin remained the only 
predictable active antibiotic against all strains of S. 
aureus, and MRSA in particular [24]. Until recently 
no strains of S. aureus have failed to respond to 
Vancomycin, providing Vancomycin could reach 
the site of infection [9]. The recent discovery of 
VRSA has been to many microbiologists a 
nightmare scenario [10]. In May 1997, the Center 
for Disease Control & Prevention (CDC) confirmed 
that it has documented the first failure of 
Vancomycin in Japan [11,25]. In New York (1998) 
a man died of the same VRSA [12,18]. VRSA was 
first reported in Brazil in 1998 [13]. These strains 
are generally in the intermediate level of 
resistance to Vancomycin, with moderately raised 
minimal inhibitory concentrations (MICs), 
previously described as Vancomycin intermediate 
strains of S. aureus (VISA). However, they are 
frequently also resistant to the other glycopeptides 
used in clinical practice (teicoplanin) and are 
therefore more accurately described as GISA 
(glycopeptide intermediate S. aureus). They 
appear to have developed from strains of MRSA 
[10,15,19,20]. 
We are continuously isolating increasing 
numbers of MRSA, especially from hospitalized 
patients [16]. Fortunately, we have therapeutic 
options besides Vancomycin but it is almost 
inevitable that with time these strains will become 
resistant to all currently available agents. Hence, 
the main objective of this study was to monitor the 
current status of Vancomycin susceptibility for the 
possible presence of Vancomycin resistant or 
intermediate strains of S.aureus in Karachi, 
especially in hospitalized patients. These isolates 
were tested not only against recommended 
antibiotics, but also against different natural or 
semi–natural products such as caffeine, neem leaf 
extract (Azadirachta indica) and Amoxycassia 
(Amoxil + Cassia fistula). Caffeine has antioxidant 
and antibacterial properties, whereas neem is 
already in use in alternative medicine for chronic 
malarial fever, liver problems and skin ulcers [21].  
 
Material and methods 
A total of 850 clinical isolates of Staphylococcus 
aureus from different specimens including purulent 
drainage, wound swabs, urine, ear swabs and 
blood were selected for this study between 
February 2006 and January 2007. This selection 
was made on the basis of Spot tests: 1) 
morphological characteristics (Gram positive cocci 
arranged in bunches and scattered, non-
capsulated, non-sporulated and a-flagellated), 2) 
biochemical characteristics (catalase positive, 
coagulase positive by the slide method, 
thermonuclease positive and beta-lactamase 
producer), and 3) colonial characteristics, i.e. 
round, off- white to golden yellow pigment, 
convex, entire margin on nutrient agar, mannitol 
fermenter, mostly beta hemolytic, DNAse 
producers, pink to mauve colonies of coagulase 
positive S. aureus (CoPSA) and off-white to cream 
colonies of MRSA on CMCSA (CHROMagar 
Rambach, France). 
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To make bacterial suspensions, four to five 
colonies of pure growth from overnight cultures of 
target strains were transferred into a tube 
containing four to five ml of trypticase soy broth 
(Merck, Germany), and incubated at 37° C to 
match the turbidity with  Mcfarland index of 0.5 
(usually 2-6 hours). Lawns of each bacterial 
suspension were made on Mueller Hinton’s agar 
(MHA) (Merck, Germany) using sterile cotton 
swabs. Antibiotic discs (Gentamicin, Methicillin, 
Erythromycin, Oxacillin, Ampiclox, Amikacin, and 
Tetracycline) (Oxoid) were positioned at 
appropriate distances on the bacterial lawns and 
incubated at 37ºC for 24 hours. The growth 
inhibition zones were carefully measured with 
calipers and recorded according to the standard 
Kirby Bauer disc diffusion method and NCCLS 
guidelines (Staphylococcus spp. for which the MIC 
of Vancomycin is <  4 µg/ml are considered 
susceptible). Isolates for which the MIC is 4-8 
µg/ml are intermediate and those for which the 
MIC is >16 µg/ml are resistant [32]. The 250 
isolated MRSA strains were checked for sensitivity 
to Vancomycin using E-test strips (AB Biodisk, 
USA). Bacterial lawns were made on MHA and 
then the E-test strips were positioned on the agar 
surface with sterile forceps, and incubated at 37°C 
for 24 hours. The MICs of Vancomycin from E-Test 
strips were noted according to the manufacturer’s 
guidelines (AB-biodisk, USA) and the NCCLS 
standards of 2003 [33]. 
 
Results 
This study was conducted on 850 clinical 
isolates of S. aureus obtained from hospitalized 
patients in Karachi between February 2006 and 
January 2007. Of these, 250 isolates were 
identified as Methicillin resistant S. aureus 
(MRSA), as determined by susceptibility to 
Methicillin discs and growth on CMCSA agar. 
Beta-lactamase production among tested strains 
was checked by Iodometric methods and 
Nitrocefin® sticks. By iodometric methods 44% of 
total isolates were found to be beta-lactamase 
producers, whereas with nitrocefin sticks (Oxoid) 
50% of isolates were found to be beta-lactamase 
producers. All the multiple drug resistant strains 
were beta-lactamase producers (Table 1). 
 
Table 1: Strains of Staphylococcus aureus producing 
beta-lactamase 
Test method  β-lactamase 
positive 
β-lactamase 
negative 
Iodometric 
method 
44 %  56 % 
Nitrocefin 
method 
50 %  50 % 
Antimicrobial susceptibility of S. aureus by Kirby 
& Bauer’s disk diffusion method showed that out 
of 850 isolates, 603 (70.9%) were resistant to 
Oxacillin, 416 (48.9%) resistant to Gentamicin, 
250 (29.4%) resistant to Methicillin, 255 (30 %) 
resistant to Tetracycline, 518 (60.9%) resistant to 
Erythromycin, 255 (30 %) resistant to Amikacin 
and 425 (50 %) resistant to Ampiclox. No isolates 
were found to be resistant to Vancomycin as 
measured by CLSI or NCCLS standard disk 
diffusion interpretive criteria for Vancomycin 
(organisms for which the Vancomycin zone 
diameters are ≥ 15 mm are considered 
susceptible) (Table2). 
Later, isolated Methicillin resistant strains of S. 
aureus (n=250) were tested specifically against 
different concentrations of Vancomycin by the 
agar dilution method and by E-test strips (Table 
3).  
 
Discussion 
As strains of S. aureus with reduced 
susceptibility continue to emerge and evolve, 
perhaps to full resistance, there is a clinical need 
to fully characterize them and conduct well-
designed research and epidemiological studies. 
Concern over development of VRSA emanates 
from the newly widespread occurrence of 
Vancomycin resistant strains of enterococci 
(VRE). 
VRE is more likely to occur in long-term hospital 
patients, who are also frequently colonized with 
MRSA. The presence of van A genes in VRSA 
suggests that the resistance determinant is 
acquired from a Vancomycin-resistant 
Enterococcus [29]. In fact, experimental transfer of 
the  van A genes from enterococci to S. aureus 
has been shown previously. Because Vancomycin 
remains one of the few (and in some cases the 
only) antibiotic to treat MRSA, there is concern 
that the DNA sequences encoding Vancomycin 
resistance in enterococci could be transferred to 
clinical isolates of MRSA. 
A study by Denis, et al, showed that the 
proportion of hetero-VISA strains was 0.1% of S. 
aureus and 0.4% of MRSA strains, whereas the 
proportion of VISA strains was 0.1% of S. aureus 
and 0.3% of MRSA strains [29].  
On the other hand, studies on Japanese and 
American isolates of VRSA showed that the 
mechanism of resistance in that case appears to 
be different from Vancomycin resistance in VRE. 
In some S. aureus strains resistance involves a 
markedly altered and thicker cell wall as well as 
changes in Penicillin binding proteins (PBPs) 
[30,31].  
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The present study did not detect any VRSA, but 
it is alarming that 38.4% of S. aureus isolates were 
resistant to >16 µg/ml of Vancomycin because of 
the risk of transmission of these organisms 
between patients. 
 
We are frequently unable to accurately predict 
what will happen in the future. Microbes have 
always been able to come up with unexpected and 
novel mechanisms of resistance. The emergence 
of VRSA emphasizes the importance of 
appropriate Vancomycin dosing to ensure 
complete eradication of the bacteria.  
We also should not neglect the use of 
combination therapy against MRSA. Besides, the 
effect of different natural or semi natural products 
combined with antibiotics can be tested against 
MRSA and VISA or VRSA.  
 
Conclusion 
What can we do about this? Unfortunately, once 
these strains have developed, the situation 
becomes more drastic and more difficult to deal 
with. We have to continuously monitor the 
resistance pattern of multi-drug resistant S. 
aureus. 
We need to slow down the spread and 
amplification of these strains (VISA/VRSA) as 
much as possible through good infection control, 
conservative measures, prudent use of antibiotics, 
and good hygiene. 
We should not use antibiotics unless needed, 
and when used, it is imperative that we employ an 
agent with the narrowest possible spectrum. This 
means in particular avoiding the use of agents 
such as Vancomycin, unless it is essential. 
This situation translates into a need for new 
antibiotics and novel therapeutic approaches, but it 
also stresses the need for understanding the 
mechanisms of reduced susceptibility and ultimate 
resistance. 
 
References 
1- Waldvogel FA. Staphylococcus aureus 
(including toxic shock syndrome) in Mandell GL, 
Bannett JE, Dolin R. Principles & Practice of 
Infectious Diseases. 1999 4th Ed; 2: 1745-1777. 
2-  Collignon, P et al. Antibiotic resistance: Is 
it leading to re-emergence of many infections from 
the past. Recent advances in Microbiology. Edited 
by Val Asche. Pp 203, 256. 
3-  Berber M, Rozwadowska-Dowzenko M. 
Infection by Penicillin–Resistant Staphylococci. 
Lancet.1948; 2:641-644. 
4-  Rolinson GN, Stevens S, Batchelor FR, 
Wood JC, Chain EB. Bacteriological studies on a 
new penicillin: BRL 1241. Lancet. 1960; 2:564-
567. 
5-  Jevons MP. Celbenin-resistant 
Staphylococci. BMJ. 1961; 1:124-125. 
6-  Gutmann MM. Methicillin-resistant 
Staphylococcus aureus and Vancomycin-resistant 
Enterococci: Therapeutic realities and possibilities. 
Lancet. 1997; 349:1901-1906. 
7-  Boyee JM. Are the epidemiology and 
microbiology of methicillin-resistant 
Staphylococcus aureus changing? JAMA. 1998; 
279:623-624. 
8-  Brumfitt W, Hamitton MJ. Methicillin 
resistant Staphylococcus aureus. N Eng J Med. 
1989; 320:1180-1196. 
9-  Maple PAC, et al. Worldwide antibiotic 
resistance in methicillin-resistant Staphylococcus. 
Lancet. 1989; 1:537-540. 
10-  Moreno F, Crisp C, Jorgensen JH, 
Patterson JE. Methicillin-resistant Staphylococcus 
aureus as a community organism. Clin Inf Dis. 
1995; 21:1308-1312. 
11-  Smith TL, Pearson ML, Wilcox KR, et al. 
Emergence of Vancomycin-resistant 
Staphylococcus aureus. N Eng J Med. 1999; 
340:537-540. 
12-  Hiramatsu K, Aritaka N, Hanaki H, 
Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, 
Kobayashi I. Dissemination in Japanese hospitals 
of strains of Staphylococcus aureus 
heterogeneously resistant to Vancomycin. Lancet. 
1997; 350:1670-1673. 
13-  Sieradzki K, Roberts RB, Haber SW, 
Tomasz A.. The development of Vancomycin-
resistance in patients with methicillin-resistant 
Staphylococcus aureus infection. N Eng J Med. 
1999; 340:517-523. 
14-  Smith TL, Pearson ML, Wilcox KR, Cruz 
C, Lancaster MV, Robinson-Dunn B, Tenover FC, 
Zervos MJ, Band JD, White E, Jarvis WR. 
Emergence of Vancomycin-resistance in 
staphylococcus aureus. N Eng J Med. 1999; 
340:493-501 
15- Waldvogel FA. New resistance in 
Staphylococcus aureus. N Eng J Med. 1999; 
340:556. 
16-  Lambert PH., Grady WF. 1992. Antibiotics 
& Chemotherapy. 6th Ed. 
17-  Collignon P, et al. Community acquired 
methicillin-resistant Staphylococcus aureus in 
Australia. Lancet. 1998; 352:145. 
18-  Hiramatsu K, Hanaki H, Ino T, Yabuta K, 
Oguri T, Tenover FC. Methicillin-resistant 
Staphylococcus aureus clinical strain with reduced 
Vancomycin succeptibility. J Antimicrob 
Chemotherap. 1997;  40:135-136. 
Page 178   
Original Article   
www.ljm.org.ly
 
 
 
  Libyan J Med, AOP: 070624
 
19-  Brunet F, Vedel G, Dreyfus F, Vaxelaire 
JF, Giraud T, Schremmer B, Monsallier JF. Failure 
of teicoplanin therapy in two neutropenic patients 
with staphylococcal septicemia who recovered 
after administration of Vancomycin. Eur J Clin 
Microb Infec Dis. 1990; 9:145-147. 
20-  Tenover F, et al. Characterization of 
Staphylococci with reduced susceptibilities to 
Vancomycin and other glycopeptides. J Clin 
Microbiol. 1998; 34(4):1020-1024. 
21-  The Encyclopedia of plants.  Andrew 
Chevalier, DK Publishing, London. 1996. 
22-  Lisa Waltz ND. The herbal encyclopedia: 
A practical guide to the many uses of herbs. 
(unpublished in traditional form, available as an 
electronic book (e-book) from earthnow. org. 1999-
2000 
23-  Hafiz S, Hafiz AN, et al. Methicillin 
resistant Staphylococcus aureus: A multicentre 
study. J Pak Med Assoc. 2002; 52 (7): 312-314. 
24-  Rubeena H, Maleeha A, Shahbaz A. 
Incidence of Methicillin resistant Staphylococcus 
aureus in blood culture isolates a-retrospective 
study. Ann King Edward Med Coll. 2001; 7(4): 
264-266. 
25-  Shahla L, Anwer MS, Chaudhry NA. 
Susceptibility pattern of Nosocomial methicillin 
resistant Staphylococcus aureus (MRSA) isolates 
to Vancomycin and other anti-staphylococcal 
antibiotics. Biomedica. 2000; 16: 32-35.  
26-  Karamat AK, Nadeem RA, Abbasi SA, Butt 
T, Usman J, Hussain AB. An outbreak of 
methicillin-resistant Staphylococcus aureus. 
Pakistan J Pathol. 1996; 7(1): 24-28. 
27-  Lisa M, Lysenko C, Marcinkowski Z, 
Gwiezdzinski Z. Performance of the chromogenic 
CHROMagar Staph aureus and the Staphychrom 
coagulase test in the detection and identification of 
Staphylococcus aureus in clinical specimens. J 
Clin Microbiol. 2001; 39(7): 2581-2583. 
28-  Merlino J, Leroi M, Bradbury R, Veal D, 
Harbour C. New Chromogenic identification and 
detection of Staphylococcus aureus and methicillin 
resistant S. aureus. J Clin Microbiol. 2000. 38(6): 
2378-2380. 
29-  Denis O, Nonhoff C, Byl B, Knoop C, 
Bobin-Dubreux S, Struelens MJ. Emergence of 
Vancomycin-intermediate Staphylococcus aureus 
in a Belgian hospital: microbiological and clinical 
features. J Antimicrob Chemother. 2002; 50: 383 – 
391. 
30-  No authors listed. Vancomycin-resistant 
Staphylococcus aureus. Pennsylvania, 2002. 
MMWR Morb Mortal Wkly Rep. 2002; 51: 902. 
31-  Noble WC, Virani Z, Cree RG. Cotransfer 
of Vancomycin and other resistant genes from 
Enterococcus faecalis NCTC 12201 to 
Staphylococcus aureus. FEMS Microbiol Lett. 
1992; 72: 195 – 198. 
32-  Clinical and Laboratory Standards 
Institute/ NCCLS. Performance standards for 
Antimicrobial Susceptibility Testing. Sixteenth 
informational supplement. M100-S16. Wayne, PA: 
CLSI, 2006. 
33-  National Committee for Clinical Laboratory 
Standards. Methods for dilution antimicrobial 
susceptibility tests for bacteria that grow 
aerobically. 6th ed. Approved standard, M7-A6. 
Wayne, Pennsylvania; 2003. 
Page 179